Drug Trial Radar · NCT02402660
Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease
Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
160
Planned (sponsor's estimate)
Start
Aug 2015
Primary completion
Jun 30, 2028
Study completion Nov 30, 2028
Sponsor
- Lead sponsor
- Alkeus Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 30, 2015
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 8 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the long term safety and tolerability of ALK-001 (C20-D3-retinyl acetate), and to explore the effects of ALK-001 on the progression of Stargardt disease in patients between the ages of 8 and 70 years old. Funding Source - FDA OOPD
Conditions
- Stargardt Disease
- Stargardt Macular Degeneration
- Stargardt Macular Dystrophy
- Autosomal Recessive Stargardt Disease 1 (ABCA4-related)
Interventions
ALK-001Drug
Daily, oral administration for 24 months
PlaceboDrug
Daily, oral administration for 24 months
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and tolerability of 24 months of daily dosing of ALK-001 assessed by incidence and/or clinically significant changes of a combination of ocular and non-ocular adverse eventsTime frame: From baseline to 24 months
Locations
14 sites in 1 country. Site status is shown where the registry gives one.
Alkeus Site
Phoenix, Arizona
Alkeus Site
Los Angeles, California
Alkeus Site
Aurora, Colorado
Alkeus Site
Gainesville, Florida
Alkeus Site
Miami, Florida
Alkeus Site
Indianapolis, Indiana
Alkeus Site
Baltimore, Maryland
Alkeus Site
Grand Rapids, Michigan
Alkeus Site
New York, New York
Alkeus Site
Westbury, New York
Alkeus Site
Houston, Texas
Alkeus Site
Salt Lake City, Utah
Alkeus Site
Silverdale, Washington
Alkeus Site
Milwaukee, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.